BP vs CTRA

BP's Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($7.35) and even the growth-based intrinsic value ($18.88), currently priced at $36.53, driven by high forward earnings expectations. While profitability metrics and dividend yield are attractive, elevated valuation multiples, inconsistent earnings surprises, and a dangerously high payout ratio of 315% raise sustainability concerns. Analysts recommend a 'buy' with a target of $38.73, supported by strong insider sentiment, though no insider transactions have occurred recently.

CTRA presents a stable financial profile with a Piotroski F-Score of 4/9 and a very healthy Debt/Equity ratio of 0.27. While the stock is trading near its Graham Number ($31.37) and well below its growth-based intrinsic value ($66.08), it is currently facing a severe bearish technical trend (10/100) and a poor recent earnings track record (1/4 beats). The primary catalyst is the pending merger with Devon Energy, which introduces significant transformative potential but also execution risk. Overall, the company is fundamentally sound but currently lacks positive price momentum and consistent earnings surprises.